Format

Send to

Choose Destination
Head Neck. 2009 Jul;31(7):893-901. doi: 10.1002/hed.21043.

Cidofovir induces an increase in levels of low-risk and high-risk HPV E6.

Author information

1
University of Manchester Gynaecological Oncology Laboratories, St. Mary's Hospital, Hathersage Road, Manchester M13 OJH, United Kingdom.

Abstract

BACKGROUND:

Cidofovir is a nucleoside analogue that is used off-license to treat recurrent respiratory papillomatosis (RRP) caused by HPV6/11. However, the effect of this drug upon low-risk HPV 6/11 gene expression is unknown.

METHODS:

The expression of E6 was evaluated by RT-PCR in HPV-ve C33A cervical carcinoma cells stably transfected with both low- and high-risk HPV E6 cDNA's and in SiHa (HPV16+ve) cervical carcinoma cells after treatment with 2 doses and durations of exposure to cidofovir.

RESULTS:

Compared to the vector only transcript, E6 RNA levels showed an 8-fold increase in low-risk and 20-fold increase in high-risk E6-expressing cells. High-risk E6 protein levels were also detected by Western blot in cidofovir-treated C33A Type16 E6-transfected cells.

CONCLUSION:

These data may indicate a potential rationale for increased risk of genetic instability and thus transformation due to drug-induced increase in the level of E6.

PMID:
19283851
DOI:
10.1002/hed.21043
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center